MRKR News & Events

Reports FY25 revenue $3.5M, consensus $3.1M. "In 2025, we continued to advance MT-601, our lead Multi-Antigen Recognizing (MAR)-T cell therapy, and generated highly encouraging clinical data from our ongoing Phase 1 APOLLO study," said Juan Vera, M.D., President and Chief Executive Officer of Marker Therapeutics. "Updated results reported last August demonstrated a 66% objective response rate in relapsed non-Hodgkin lymphoma, including durable complete responses, with a favorable safety profile across evaluated doses. During the year we also reported immunomonitoring data indicating that lymphodepletion enhances the expansion and persistence of MT-601, and we advanced the APOLLO study into dose expansion in patients with relapsed Diffuse Large B Cell Lymphoma (DLBCL). We anticipate providing a data update from the APOLLO study in the second quarter of 2026."

Marker Therapeutics announced that Baylor College of Medicine's TACTOPS clinical study in pancreatic cancer was featured on Good Morning America on Thursday, January 22, 2026. The segment spotlighted the Baylor-led research recently published in Nature Medicine evaluating autologous Multi-Antigen Targeted T cell therapy in patients with pancreatic ductal adenocarcinoma, PDAC, and highlighted the potential of Multi-Antigen Targeted approaches to address a significant unmet need in pancreatic cancer.

Marker Therapeutics is a clinical-stage immuno-oncology Company with the worldwide exclusive license of Multi-Antigen Targeted T cells, a technology developed at Baylor College of Medicine for the treatment of hematologic and solid tumors. A research team from Baylor College of Medicine has now published groundbreaking work in Nature Medicine investigating Multi-Antigen Targeted T cells in patients with pancreatic cancer. The Phase 1/2 clinical study conducted at Baylor College of Medicine demonstrated encouraging objective clinical responses and a disease control rate of 84.6% when combining Multi-Antigen Targeted T cells with frontline chemotherapy. In this arm of the study, median duration of response for patients achieving a partial or complete response was 7.5 months with a median overall survival rate of 14.1 months suggesting a clinical benefit of combining Multi-Antigen Targeted T cells with standard chemotherapy. Clinical results from this Phase 1 study demonstrated a favorable safety profile and potential synergistic effect when combining Multi-Antigen Targeted T cells with chemotherapy without affecting the toxicity profile. Chemotherapy was previously shown to break down the tumor's supporting stromal cells, which act as a protective barrier, to facilitate T cell infiltration into the tumor and to boost anti-tumor response. The research group from Baylor also highlighted a correlation between the clinical effect and the expansion and persistence of infused Multi-Antigen Targeted T cells. The data showed that infused T cells were still present in patients 12 months post-treatment and found at higher frequencies in patients that responded to the investigational product.